We performed Western blot analysis to detect anticerebellar antibodies in the serum of patients with Miller Fisher syndrome (MFS). We studied 7 MFS patients, 6 Guillain-Barré syndrome (GBS) patients and 10 normal healthy persons as controls. Six MFS patients (86%) had IgG antibodies against mouse cerebellar protein, whereas 3 GBS patients (50%) and 4 healthy controls (40%) had antibodies. The mean number of antibodies in the serum of patient with MFS was 2.43, which was significantly more than that of GBS patients (mean 0.67) and healthy control (mean 0.70). This finding suggests variability and complexity of target in nervous systems that suffer aberrant immunity in MFS, and may also reflect the variability and heterogeneity of the pathogenesis of this syndrome.

Collier J: Peripheral neuritis. Edinb Med J 1932;39:601–618.
Fisher M: An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255:57–65.
Bickerstaff ER: Brainstem encephalitis: Further observations on a grave syndrome with benign prognosis. Br Med J 1957;1:1384–1387.
Chiba A, Kusunoki S, Obata H, et al: Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: Clinical and immunohistochemical studies. Neurology 1993;43:1911–1917.
Ilyas AA, Willison HJ, Quarles RH, et al: Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol 1988;23:440–447.
Ropper AH, Wijdicks EFM, Truax BT: Guillain-Barré syndrome. Philadelphia, FA Davis Company, 1991, pp 18–21.
Laemmeli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–685.
Arnason BG: Acute inflammatory demyelinating polyradiculopathies; in Dyck PJ (ed): Peripheral Neuropathy. Philadelphia, W.B. Saunders, 1984, pp 2050–2100.
Philips MS, Stewart S, Anderson JR: Neuropathological findings in Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 1984;47:492–495.
Jamal GA, Ballantyne JP: The localization of the lesion in patients with acute ophthalmoplegia, ataxia and areflexia (Miller Fisher syndrome). A serial multimodal neurophysiological study. Brain 1988;111:95–114.
Derakhshan I, Lofti J, Kaufman B: Ophthalmoplegia, ataxia and hyporeflexia (Fisher’s syndrome) with a midbrain lesion demonstrated by CT scanning. Eur Neurol 1979;18:361–366.
Al-Din AN, Anderson M, Bickerstaff BR, Harvey I: Brain stem encephalitis and the syndrome of Miller Fisher. A clinical study. Brain 1982;105:481–495.
Van Allen MW, MacQueen JG: Ophthalmoplegia, ataxia and the syndrome of Landry-Guillain-Barré: A report of four cases with comments on the ophthalmoplegia. Trans Am Neurol Assoc 1964;89:98–103.
Schapira AHV, Thomas PK: A case of recurrent idiopathic ophthalmoplegic neuropathy (Miller Fisher syndrome). J Neurol Neurosurg Psychiatry 1986;49:463–464.
Behan PO, Geschwind N: The ophthalmoplegic form of the Guillain-Barré syndrome: An immunologic study. Act Ophthalmol (Copenh) 1973;51:529–542.
Berlit P, Rakicky J: The Miller Fisher syndrome. Review of the literature. J Clin Neuroophthalmol 1992;12:57–63.
Rees JH, Gregson A, Hughes RAC: Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995;38:809–816.
Littlewood R, Bajada S: Successful plasmapheresis in the Miller-Fisher syndrome. Br Med J (Clin Res Ed) 1981;282:778.
Koh CS, Shinoda T, Shimada K, Inoue A, Yanagisawa N: Immunoadsorption plasmapheresis and plasma exchange in Miller Fisher syndrome. Ther Plasmapheresis 1993;12:557–560.
Chiba A, Kusunoki S, Shimizu T, Kanazawa I: Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677–679.
Willison HJ, Veitch J, Paterson G, Kennedy PGE: Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry 1993;56:204–206.
O’Leary CP, Veitch J, Durward WF, Thomas AM, Rees JH, Willison HJ: Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J Neurol Neurosurg Psychiatry 1996;60:649–651.
Buchwald B, Weishaupt A, Toyka KV, Dudel J: Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci 1998;10:281–290.
Linington C, Mann A, Izumo S, Uemura K, Suzuki M, et al: Induction of experimental allergic neuritis in the BNrat: P2 protein-specific T cells overcome resistance to actively induced disease. J Immunol 1986;137:3826–3831.
Powell HC, Olee T, Brostoff SW, Mizisin AP: Comparative histology of experimental allergic neuritis induced with minimum length neuritogenic peptides by adoptive transfer with sensitized cells or directsensitization. J Neuropathol Exp Neurol 1991;50:658–674.
Hartung HP, Pollard JD, Harvey GK, Toyka KV: Immuno-pathogenesis and treatment of the Guillain-Barré syndrome-Part 1. Muscle Nerve 1995;18:137–153.
Zamvil SS, Steinman L: The T lymphocyte in experimental allergic encephalomyelitis. Ann Rev Immunol 1990;8:579–621.
Gerety SJ, Rundell MK, Dal Canto MC, Miller SD: Class II-restricted T cell responses in Theiler’s murine encephalomyelitis virus (TMEV)-induced demyelinating disease. VI. Potentiation of demyelination with and characterization of an immunopathogenic CD4+ T cell line specific for an immunodominant VP2 epitope. J Immunol 1994;152:919–929.
Stefansson K, Marton LS, Dieperink ME, Molnar GK, Schlaepfer WW, Helgason C: Circulating autoantibodies to the 200,000-dalton protein of neurofilaments in the serum of healthy individuals. Science 1985;228:1117–1119.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.